Vision - blurred
Also known as: Eyes, Vision, Visual, Sight
Methodology & AI Transparency ⓘ
Vision - blurred Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as H53.8, Vision - blurred (also termed Eyes or Vision) falls under Eyes & Vision management, where slit-lamp biomicroscopy [Vision - blurred H53.8] establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Clinical coding for Vision - blurred uses ICD-10 H53.8 across Eyes & Vision specialty care.
- 3 Typical cash cost range: Clinicians assessing Vision - blurred focus on retinal pigment epithelium in Vision - blurred (H53.8: oxidative drusen accumulation) and targeted history.
- 4 Top reported side effects / signs: Key Eyes & Vision biomarkers for Vision - blurred (H53.8): Best-Corrected Visual Acuity in Vision - blurred (H53.8: & OCT) & HbA1c & Systemic in Vision - blurred (H53.8: Blood Pressure) (Microvascular retinal protection (H53.8)).
Ask our AI Specialists anything about Vision - blurred
What Is Vision - blurred?
Designated in federal medical registries as H53.8, Vision - blurred (also termed Eyes or Vision) falls under Eyes & Vision management, where slit-lamp biomicroscopy [Vision - blurred H53.8] establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Vision - blurred (H53.8) alters eyes & vision homeostasis through retinal pigment epithelium in Vision - blurred (H53.8: oxidative drusen accumulation); clinical remission targets HbA1c & Systemic in Vision - blurred (H53.8: Blood Pressure) within Microvascular retinal protection (H53.8).
Common Symptoms & Clinical Signs
- • Presentation of Vision - blurred (H53.8): acute eye redness, in Vision - blurred (H53.8: discharge, photophobia, or)
- • Secondary Vision - blurred clinical sign: gradual blurring, glare/halos in Vision - blurred (H53.8: around nighttime headlights,)
- • Symptom flares in Vision - blurred correlating with Best-Corrected Visual Acuity in Vision - blurred (H53.8: & OCT) deviation outside Intact retinal nerve fiber & macula (H53.8)
- • Functional eyes & vision impact requiring slit-lamp biomicroscopy [Vision - blurred H53.8] evaluation (H53.8)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Vision - blurred Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | H53.8 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Eye Health, Glaucoma & Vision Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Best-Corrected Visual Acuity in Vision - blurred (H53.8: & OCT) | Intact retinal nerve fiber & macula (H53.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HbA1c & Systemic in Vision - blurred (H53.8: Blood Pressure) | Microvascular retinal protection (H53.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Intraocular Pressure (IOP) [Vision - blurred H53.8] | 10 – 21 mmHg (individualized optic target) (H53.8) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Vision - blurred
Treatment selection for Vision - blurred depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Vision - blurred)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Brodalumab in psoriatic arthritis: results from the randomised phase III: What a 962-Participant Study Found Brodalumab was associated with rapid and significant improvements in signs and symptoms of PsA versus placebo. Annals of the rheumatic diseases • 2021-02-15 • Phase III Randomized Trial | N = 962 | 93/100 | PMID 33106286 ↗ |
| Can This Approach Help? Inside the Latest Research on A clinical multimodal vision language foundation model with fine-grain Indexed from Nature Medicine (2026-10-29) by DotMD's 2-hour clinical surveillance pipeline. Nature Medicine • 2026-10-29 • Peer-Reviewed Journal (Longevity & Biotech) | Multi-cohort | 92/100 | PMID NATURE_MED-3254811141 ↗ |
| Managing Acute liver porphyria: Can Disease burden Make a Real Difference? (What New Research Reveals) Patients with AHP, regardless of annualized attack rates, have considerable disease burden that may partly be alleviated with givosiran. Orphanet journal of rare diseases • 2022-08-26 • Phase III Randomized Trial | N = 46 | 88/100 | PMID 36028858 ↗ |
| New Insights on Vision-Related Quality of Life in Geographic Atrophy: Association with: What a 856-Participant Study Found In this cohort, VR-QoL is most strongly associated with minimum eye-level GA extent within the central 2.50-mm region within an individual. Ophthalmology • 2026-08-15 • Phase III Randomized Trial | N = 856 | 87/100 | PMID 42031134 ↗ |
| New Insights on OCT Grading System of Macular Infarction Predicts Vision in Participants With: What a 362-Participant Study Found Participants with more severe macular infarction at M01, as graded with OCT, exhibited worse visual outcomes despite significantly improved macular edema from month 6 to 5 years. American journal of ophthalmology • 2023-12-15 • Phase III Randomized Trial | N = 362 | 87/100 | PMID 37544495 ↗ |
Vision - blurred Patient Community & “People Like Me” Threads
Filter Vision - blurred community threads and patient logs by age, biological sex, dosage, and treatment duration.